About: Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells
Creator	Cao, Xuetao Wang, Qingqing Dai, Shengming Zhou, Xiangyang Wan, Tao Wang, B Yu, Y Zhou, X Chen, Taoyong Fu, Yangxin Cao, : Chen, : Dai, S Fu, : Wan, T Wang, : Wang, Baomei Yu, Yizhi Zhou, :
source	Medline; PMC
abstract	Dendritic cells (DC)-derived or tumor-derived exosomes are a population of nanometer sized membrane vesicles that can induce specific anti-tumor immunity. However, the immunogenic potential and efficiency of exosomes-based tumor vaccine are not satisfactory enough to achieve a curative effect in clinical trials. In this article we investigated whether IL-18 genetic modification of tumor cells can increase the efficacy of exosomes derived from IL-18 gene-modified tumor cells. We transfected carcinoembryonic antigen (CEA)-expressing tumor cells with a recombinant adenovirus encoding human IL-18 (AdhIL-18) and prepared the exosomes, Exo/IL-18, from IL-18 gene-modified tumor cells. We found that Exo/IL-18 naturally contain CEA and bioactive IL-18. Moreover, Exo-IL-18 are potent in chemoattracting DC and T cells, enhancing the proliferation and Th1 cytokine release of PBMC, and promoting the phenotypic and functional maturation of DC. Furthermore, Exo/IL-18-pulsed DC are quite potent to induce HLA-A0201-restricted, CEA-specific CD8(+) CTL from the PBMC of HLA-A0201 CEA(+) cancer patients in vitro. In almost all of these experiments, Exo/IL-18 show more potent functions than the conventionally prepared exosomes derived from parent tumor cells without IL-18 gene modification. Our findings suggest that Exo/IL-18 has more potent capability to induce specific anti-tumor immunity, and our strategy of IL-18 modification of exosomes is a feasible approach to develop exosomes-based tumor vaccines.
has issue date	2006-09-26(xsd:dateTime)
bibo:doi	10.1007/s00109-006-0102-0
bibo:pmid	17016692
has license	no-cc
sha1sum (hex)	f7cdd1401f92aa073bd886ef3025e77792da5875
schema:url	https://doi.org/10.1007/s00109-006-0102-0
resource representing a document's title	Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells
has PubMed Central identifier	PMC7079873
has PubMed identifier	17016692
schema:publication	J Mol Med (Berl)
resource representing a document's body	covid:f7cdd1401f92aa073bd886ef3025e77792da5875#body_text
is schema:about of	named entity 'specific' named entity 'human' named entity 'induce' named entity 'potential' named entity 'vaccine' named entity 'immunity' named entity 'tumor' named entity 'T cells' named entity 'CTL' named entity 'response' named entity 'induction' named entity 'FUNCTIONS' named entity 'MATURATION' named entity 'MEMBRANE' named entity 'DERIVED' named entity 'INVESTIGATED' named entity 'PBMC' named entity 'GENE MODIFICATION' named entity 'TUMOR IMMUNITY' named entity 'PROMOTING' named entity 'CARCINOEMBRYONIC ANTIGEN' named entity 'GENETIC MODIFICATION' named entity 'SIZED' named entity 'EFFECT' named entity 'CURATIVE' named entity 'BASED' named entity 'ALMOST ALL' named entity 'RECOMBINANT ADENOVIRUS' named entity 'ENOUGH' named entity 'POTENTIAL' named entity 'ENHANCING' named entity 'FOUND' named entity 'FEASIBLE' covid:arg/f7cdd1401f92aa073bd886ef3025e77792da5875 named entity 'RESTRICTED' named entity 'TUMOR CELLS' named entity 'EXOSOMES' named entity 'CTL' named entity 'RESPONSE' named entity 'SPECIFIC' named entity 'TUMOR-DERIVED' named entity 'NANOMETER' named entity 'DERIVED' named entity 'CD8' named entity 'POSITIVE' named entity 'CEA' named entity 'INDUCTION' named entity 'IL-18 GENE' named entity 'DENDRITIC CELL MATURATION' named entity 'PATIENTS' named entity 'HLA-A' named entity 'CAPABILITY' named entity 'DENDRITIC CELLS' named entity 'EXPERIMENTS' named entity 'HUMAN' named entity 'VESICLES' named entity 'INCREASE' named entity 'TH1 CYTOKINE' named entity 'GENE-MODIFIED' named entity 'ENHANCED' named entity 'TUMOR VACCINES' named entity 'EFFICACY' named entity 'STRATEGY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software